Symbiosis rolls out first 10,000 vial batch at Stirling Facility
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Subscribe To Our Newsletter & Stay Updated